BioSpace News Archive

Less than one month after announcing plans for construction of a South Carolina manufacturing facility, Arthrex announces its plans for the expansion of its global headquarters in Florida.

The company appointed former Celgene president Michael Pehl as CEO and Brendan Delaney as CCO.

The price of $1.46 per Unit represents the market price of Neovasc’s common shares as of the date of this news release.

Preliminary results from the single agent portion of the trial (NCT03013218) showed that ALX148 is generally well tolerated in patients with advanced malignancy, with no dose-dependent impact on normal blood cells.

Valeant will use approximately $180M of the net proceeds from the sale to repay term loan debt under its Senior Credit Facility.

Net revenues totaled $17.6M, an increase of 2.1%, versus the third quarter of 2016 of $17.2M.

Zydus today announced that the Mexico regulatory authority COFEPRIS has granted marketing approval to commercialize Lipaglyn (Saroglitazar Magnesium) in Mexico for the treatment of Dyslipidemia in patients with diabetes mellitus type 2 and Hypertriglyceridemia in patients with diabetes mellitus type 2 not controlled by statins.

ABP 215 has been recommended for approval for the treatment of certain types of cancer, including in combination with fluoropyrimidine-based chemotherapy for metastatic carcinoma of the colon or rectum.

Second Sight Medical Products announced that the Argus II Retinal Prosthesis System (“Argus II”) has been recommended for public funding by the Ontario Health Technology Advisory Committee (OHTAC) of Health Quality Ontario.

Dynatronics today announced that its financial results for the quarter ended September 30, 2017 will be released pre market open on Tuesday, November 14, 2017.